THC and CBD oromucosal spray (Sativex^®) in the management of spasticity associated with multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343, 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transaction in the lesions of multiple sclerosis. N. Engl. J. Med.338, 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess.6, 1–73 (2002).
   PubMedGoogle Scholar
• Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol.12(Suppl. 1), 63–67 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil.24, 293–304 (2010).
   PubMed Web of Science ®Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10, 589–595 (2004).
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev.2, CD001332 (2004).
   Google Scholar
• Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler.12, 646–651 (2006).
   PubMed Web of Science ®Google Scholar
• Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today42, 495–501 (2006).
   PubMed Web of Science ®Google Scholar
• Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract.59, 291–295 (2005).
   PubMed Web of Science ®Google Scholar
• Russo EB. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag.4, 245–249 (2008).
   PubMedGoogle Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol.147, S163–S171 (2006).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol.18, 129–140 (2007).
   PubMed Web of Science ®Google Scholar
• Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol.150, 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil.17(1), 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler.10(4), 425–433 (2004).
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ329(7460), 253 (2004).
   PubMed Web of Science ®Google Scholar
• Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol.38(1), 44–48 (1997).
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A; on behalf of the UK MS Research Group. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet362, 1517–1526 (2003).
   PubMed Web of Science ®Google Scholar
• Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Aldington S, Harwood M, Cox B; on behalf of the Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case–control study. Eur. Resp. J.31, 280–286 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez-Rodriguez JE, Munteis E, Carreňo M et al. Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients’ expectations? J. Neurol. Sci.273, 103–107 (2008).
   PubMed Web of Science ®Google Scholar
• Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0–10 Numerical Rating Scale. J. Neurol.254(Suppl. 3), 21 (2007).
   Google Scholar
• Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J. Neurol. Neurosurg. Psychiatry81(1), 46–52 (2010).
   PubMed Web of Science ®Google Scholar
• Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol.15(Suppl. 3), 365 (2008).
   Google Scholar
• Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler.12, 639–645 (2006).
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler.13, S129 (2007).
   Google Scholar
• Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res.32, 451–459 (2010).
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. doi: 10.1111/j.1468–1331.2010.03328.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Notcutt W, Davies P, Langford R, Ratcliffe S. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long term Sativex®. Mult. Scler.15, S258 (2009).
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler.16, 1349–1359 (2010).
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology65, 812–819 (2005).
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin. Ther.29, 2068–2079 (2007).
   PubMed Web of Science ®Google Scholar
• Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler.16, 707–714 (2010).
   PubMed Web of Science ®Google Scholar
• Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler.15, S272 (2009).
   PubMed Web of Science ®Google Scholar
• House H, Bateman C, Wade DT. Long-term Sativex (THC:CBD) use in multiple sclerosis: benefits to daily life and functional activities. Mult. Scler.13, S267 (2007).
   Google Scholar
• Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex® in patients with multiple sclerosis. Mult. Scler.12, S111 (2006).
   Google Scholar
• Sativex oromucosal spray: summary of product characteristics. Almirall, Spain (2010).
   Google Scholar
• Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend.42, 201–207 (1996).
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can. J. Psych.51, 556–565 (2006).
   Google Scholar
• Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum. Psychopharmacol.19, 97–101 (2004).
   PubMed Web of Science ®Google Scholar
• Iversen L. Long-term effects of exposure to cannabis. Curr. Opin. Pharmacol.5, 69–72 (2005).
   PubMed Web of Science ®Google Scholar
• Aragona M, Onesti E, Tomassini V et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol.32, 41–47 (2009).
   PubMed Web of Science ®Google Scholar
• Schoedel K, Chen N, Guy GW et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur. Neuropsychopharmacol.20(Suppl. 3), S587 (2010)
   Google Scholar
• Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin. Ther.28, 445–460 (2006).
   PubMed Web of Science ®Google Scholar